Glenmark acquires Acetylcysteine injection, launches in US market
Glenmark Pharmaceuticals Inc., USA announced today the acquisition and launch of Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials in the US market.
The shares of Glenmark Pharmaceuticals Limited were trading at ₹1,286.30, up by ₹7.35 or 0.57 per cent on the NSE today at 10.13 am.
The company acquired the Abbreviated New Drug Application (ANDA) for the product from Aspen Pharma USA Inc. The injection is therapeutically equivalent to Cumberland Pharmaceuticals’ Acetadote Injection, which achieved annual sales of approximately $15.2 million for the 12-month period ending January 2025, according to IQVIA data.
Marc Kikuchi, President & Business Head, North America, stated the acquisition strengthens Glenmark’s injectable portfolio as the company continues to focus on growth in the hospital segment.
Glenmark Pharmaceuticals Ltd. is a global pharmaceutical company with operations in over 80 countries and 11 manufacturing facilities across four continents. The company focuses on respiratory, dermatology, and oncology therapeutic areas across its branded, generic, and OTC segments.
The company ranks among the top 100 biopharmaceutical companies by pharmaceutical sales according to Scrip 100, and in the top 50 generics and biosimilar companies by sales according to Generics Bulletin. In 2023, Glenmark’s Green House Gas emission reduction targets were approved by the Science Based Target initiative, making it the second pharmaceutical company in India to achieve this milestone.
